Journal of Neurology

, Volume 266, Issue 1, pp 207–211 | Cite as

Urinary symptoms, quality of life, and patient satisfaction in genetic and sporadic hereditary spastic paraplegia

  • Susanne A. SchneiderEmail author
  • Viktoria E. Beckinger
  • Bettina Möller
  • Stephanie Knüpfer
  • Moritz Hamann
  • Günther Deuschl
Original Communication



Urinary involvement is common in hereditary spastic paraplegias (HSPs), but has rarely been assessed systematically.


We characterized urinary complaints in 71 German HSP patients (mean age 55.4 ± 13.9 years; mean disease duration 20.7 ± 14.3 years; 48% SPG4-positive) using validated clinical rating scales (SCOPA-AUT, ICIQ-SF, ICIQ-LUTSqol). Treatment history and satisfaction with medical care was also assessed.


74.6% of patients had one or more urological problems, most commonly nocturia and urgency. Incontinence was more severe in women, correlating with SCOPA-AUT. Female gender and SPG4 mutations were associated with higher urinary frequency and severity of urological involvement. QoL was overall reduced, more in women and in SPG4 mutation carriers. Almost 90% consulted a medical specialist; more than half were largely satisfied. 43.4% received oral medication and 5.7% received intravesical botulinum toxin. However, more than one-third of patients remained untreated.


Urinary complaints are common in HSP and should be addressed and treated.


Hereditary spastic paraplegia Bladder SPG4 Satisfaction with care Urinary incontinence Nocturia Urgency Urinary frequency Urinary hesitancy SCOPA-AUT Quality of life International Consultation on Incontinence Questionnaire 



We thank Rudolf Kleinsorge on behalf of the Förderverein für HSP-Forschung for help with patient recruitment. The study was awarded the Eugen Rehfisch Prize 2018. We thank Baccara Hizli for administrative assistance.

Author contributions

SAS: research project: conception, organization, execution; statistical analysis: review and critique; manuscript: writing of the first draft. VB: research project: organization ad execution; statistical analysis: execution; manuscript: review and critique. BM: statistical analysis: design, execution, review and critique; manuscript: review and critique. SK: manuscript: review and critique. GD: manuscript: review and critique.

Compliance with ethical standards

Financial disclosure

SAS was supported by the Else Kröner-Fresenius-Stiftung. GD has received lecture fees from Boston Scientific and has been serving as a consultant for Boston Scientific. He received royalties from Thieme publishers. He is a government employee and receives through his institution funding for his research from the German Research Council, the German Ministry of Education and Research, and Medtronic.

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.


  1. 1.
    de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, Bortholin T, Oliveira ASB (2017) Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum 16:525–551CrossRefGoogle Scholar
  2. 2.
    Braschinsky M, Zopp I, Kals M, Haldre S, Gross-Paju K (2010) Bladder dysfunction in hereditary spastic paraplegia: what to expect? J Neurol Neurosurg Psychiatry 81:263–266CrossRefGoogle Scholar
  3. 3.
    Fourtassi M, Jacquin-Courtois S, Scheiber-Nogueira MC et al (2012) Bladder dysfunction in hereditary spastic paraplegia: a clinical and urodynamic evaluation. Spinal Cord 50:558–562CrossRefGoogle Scholar
  4. 4.
    Joussain CL, Charlanes J, Even A, Falcou A, Chartier-Kastler L, Denys EP (2016) Neurogenic detrusor overactivity in patients with hereditary spastic paraplegias. Ann Phys Rehabil Med 59S:e104CrossRefGoogle Scholar
  5. 5.
    Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. European urology 50:1306–1314 (discussion 1314-1305) CrossRefGoogle Scholar
  6. 6.
    Yeo L, Singh R, Gundeti M, Barua JM, Masood J (2012) Urinary tract dysfunction in Parkinson’s disease: a review. Int Urol Nephrol 44:415–424CrossRefGoogle Scholar
  7. 7.
    Wyndaele JJ (1999) Normality in urodynamics studied in healthy adults. J Urol 161:899–902CrossRefGoogle Scholar
  8. 8.
    Schule R, Wiethoff S, Martus P et al (2016) Hereditary spastic paraplegia: clinicogenetic lessons from 608 patients. Ann Neurol 79:646–658CrossRefGoogle Scholar
  9. 9.
    Fjermestad KW, Kanavin OJ, Naess EE, Hoxmark LB, Hummelvoll G (2016) Health survey of adults with hereditary spastic paraparesis compared to population study controls. Orphanet J Rare Dis 11:98CrossRefGoogle Scholar
  10. 10.
    Vahter L, Braschinsky M, Haldre S, Gross-Paju K (2009) The prevalence of depression in hereditary spastic paraplegia. Clin Rehabil 23:857–861CrossRefGoogle Scholar
  11. 11.
    Sperfeld AD, Unrath A, Kassubek J (2007) Restless legs syndrome in hereditary spastic paraparesis. Eur Neurol 57:31–35CrossRefGoogle Scholar
  12. 12.
    Martin JL, Williams KS, Abrams KR et al (2006) Systematic review and evaluation of methods of assessing urinary incontinence. Health Technol Assess 10:1–132, iii-ivCrossRefGoogle Scholar
  13. 13.
  14. 14.
    Braschinsky M, Rannikmae K, Krikmann U et al (2011) Health-related quality of life in patients with hereditary spastic paraplegia in Estonia. Spinal Cord 49:175–181CrossRefGoogle Scholar
  15. 15.
    Visco AG, Brubaker L, Jelovsek JE et al (2016) Adherence to oral therapy for urgency urinary incontinence: results from the anticholinergic versus Botox comparison (ABC) trial. Female Pelvic Med Reconstr Surg 22:24–28CrossRefGoogle Scholar
  16. 16.
    Ni J, Wang X, Cao N, Si J, Gu B (2017) Is repeat botulinum toxin a injection valuable for neurogenic detrusor overactivity—a systematic review and meta-analysis. Neurourol Urodyn 37:542–553CrossRefGoogle Scholar
  17. 17.
    Kaviani A, Khavari R (2017) Disease-specific outcomes of botulinum toxin injections for neurogenic detrusor overactivity. Urol Clin North Am 44:463–474CrossRefGoogle Scholar
  18. 18.
    Mehta S, Hill D, McIntyre A et al (2013) Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury. Arch Phys Med Rehabil 94:1473–1481CrossRefGoogle Scholar
  19. 19.
    Knupfer SC, Schneider SA, Averhoff MM et al (2016) Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease. BMC Urol 16:55CrossRefGoogle Scholar
  20. 20.
    Niu HL, Ma YH, Zhang CJ (2018) Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: a systematic review and meta-analysis of randomized controlled trials. Int J Surg. Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Susanne A. Schneider
    • 1
    • 2
    Email author
  • Viktoria E. Beckinger
    • 1
  • Bettina Möller
    • 1
  • Stephanie Knüpfer
    • 3
  • Moritz Hamann
    • 3
  • Günther Deuschl
    • 1
  1. 1.Department of NeurologyChristian-Albrechts-University KielKielGermany
  2. 2.Department of NeurologyLudwig-Maximilians-University MünchenMunichGermany
  3. 3.Department of UrologyChristian-Albrechts-University KielKielGermany

Personalised recommendations